Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palvella Therapeutics ( (PVLA) ) just unveiled an announcement.
On June 10, 2025, Palvella Therapeutics held its Annual Meeting of Stockholders virtually, where key decisions were made regarding the company’s governance and financial oversight. Elaine J. Heron, Ph.D., and Tadd S. Wessel were elected as Class II directors, and Ernst & Young LLP’s appointment as the independent registered public accounting firm for 2025 was ratified. Additionally, the stockholders approved the compensation of the company’s named executive officers for 2024, indicating continued support for the company’s leadership and strategic direction.
The most recent analyst rating on (PVLA) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.
Spark’s Take on PVLA Stock
According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.
Palvella Therapeutics’ overall score reflects significant financial challenges, particularly in revenue and profitability, which are partially offset by a robust cash position and no debt. Positive corporate developments, such as clinical advancements and strategic financing, provide potential growth opportunities. However, valuation concerns due to negative earnings and the absence of dividends weigh on the score.
To see Spark’s full report on PVLA stock, click here.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing treatments for rare and serious diseases. The company is committed to advancing its pipeline of therapeutic candidates to address unmet medical needs.
Average Trading Volume: 81,498
Technical Sentiment Signal: Hold
Current Market Cap: $290M
Find detailed analytics on PVLA stock on TipRanks’ Stock Analysis page.